Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib

Context: The RAF inhibitor vemurafenib has provided a major advance for the treatment of patients with BRAF-mutant metastatic melanoma. However, BRAF-mutant thyroid cancer is relatively resistant to vemurafenib, and the reason for this disparity remains unclear. Anti-cancer therapy induced autophagy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of clinical endocrinology and metabolism 2017-02, Vol.102 (2), p.634-643
Hauptverfasser:	Wang, Weibin, Kang, Helen, Zhao, Yinu, Min, Irene, Wyrwas, Brian, Moore, Maureen, Teng, Lisong, Zarnegar, Rasa, Jiang, Xuejun, Fahey, Thomas J
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Antitumor activity Autophagy Autophagy - drug effects Cancer therapies Cell death Cell Line, Tumor Cell viability Cellular stress response Clinical s Drug resistance Editor's Choice Electron microscopy Endoplasmic reticulum Endoplasmic Reticulum Stress - drug effects Growth rate Humans Hydroxychloroquine Indoles - pharmacology Inhibition Male MAP kinase Melanoma Metastases Mice Mice, SCID Mutants Mutation Phagocytosis Proto-Oncogene Proteins B-raf - genetics Raf protein Ribonucleic acid RNA Signal transduction Stress Stress response Sulfonamides - pharmacology Thyroid cancer Thyroid Neoplasms - drug therapy Thyroid Neoplasms - genetics Transmission electron microscopy Tumor suppression Tumors Vemurafenib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!